Streetbeat News

Price Targets

MCRB

Goldman Sachs analyst Chris Shibutani has maintained a 'Sell' rating on Seres Therapeutics (NASDAQ:MCRB) and lowered the price target from $4 to $1.25.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:58 pm

SNDR

Goldman Sachs analyst Jordan Alliger has maintained a Neutral rating on Schneider National (NYSE:SNDR) and lowered the price target from $32 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:57 pm

RDFN

Wedbush analyst Jay McCanless has maintained a Neutral rating on Redfin (NASDAQ:RDFN) and lowered the price target from $11 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:57 pm

PHAT

Goldman Sachs analyst Paul Choi maintains a Neutral rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:55 pm

PTON

Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on Peloton Interactive (NASDAQ:PTON) and lowered the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:54 pm

QLYS

Wedbush analyst Daniel Ives maintains an Outperform rating on Qualys (NASDAQ:QLYS) and raises the price target from $160 to $170.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:53 pm

MRNA

Goldman Sachs analyst Salveen Richter maintains a Buy rating on Moderna (NASDAQ:MRNA) but lowers the price target from $269 to $231.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:51 pm

KBR

Goldman Sachs analyst Jerry Revich maintains a Buy rating on KBR (NYSE:KBR) but lowers the price target from $75 to $66.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:48 pm

KRTX

Goldman Sachs analyst Corinne Jenkins has maintained a 'Buy' rating on Karuna Therapeutics (NASDAQ:KRTX), but lowered the price target from $332 to $296.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:47 pm

IONS

Goldman Sachs analyst Salveen Richter maintains a 'Sell' rating on Ionis Pharmaceuticals (NASDAQ:IONS) but raises the price target from $25 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:44 pm